Understanding the role of gpcr heteroreceptor complexes in modulating the brain networks in health and disease

Frontiers in Cellular Neuroscience

Volumn 11, Issue , 2017, Pages

  Borroto Escuela, Dasiel O ^a,b,c   Carlsson, Jens ^d   Ambrogini, Patrizia ^b   Narváez, Manuel ^e   Wydra, Karolina ^f   Tarakanov, Alexander O ^g   Li, Xiang ^a   Millón, Carmelo ^e   Ferraro, Luca ^h   Cuppini, Riccardo ^b   Tanganelli, Sergio ^h   Liu, Fang ⁱ   Filip, Malgorzata ^f   Diaz Cabiale, Zaida ^e   Fuxe, Kjell ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF URBINO   (Italy)

^c Grupo Bohio Estudio   (Cuba)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSIDAD DE MÁLAGA   (Spain)

^f INSTITUTE OF PHARMACOLOGY   (Poland)

^g ST PETERSBURG INSTITUTE FOR INFORMATICS AND AUTOMATION   (Russian Federation)

^h UNIVERSITY OF FERRARA   (Italy)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

Addiction; Depression; Dopamine receptor; G protein coupled receptor; Heteroreceptor complexes; Oligomerization; Schizophrenia; Serotonin receptor

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE; ADENOSINE A2A RECEPTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 39; GALANIN; GALANIN RECEPTOR 1; GALANIN RECEPTOR 2; GLUTAMIC ACID; IMIPRAMINE; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTENSIN; NEUROTENSIN RECEPTOR 1; OXYTOCIN; OXYTOCIN RECEPTOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; ZINC;

ALLOSTERISM; ANTIDEPRESSANT ACTIVITY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BRAIN DISEASE; COCAINE DEPENDENCE; DRUG TARGETING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIPPOCAMPUS; HUMAN; LONG TERM MEMORY; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL NETWORK; NEUROMODULATION; NONHUMAN; OLIGOMERIZATION; POSTSYNAPTIC MEMBRANE; PROTEIN PROTEIN INTERACTION; PSYCHOPHARMACOLOGY; REVIEW; REWARD; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VENTRAL STRIATUM;

EID: 85013948953     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2017.00037     Document Type: Review

References (177)

1. Agnati, L. F., Celani, M. F., and Fuxe, K. (1983a). Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites. Acta Physiol. Scand. 118, 79–81. doi: 10.1111/j.1748-1716.1983.tb07244.x
2. Agnati, L. F., Fuxe, K., Benfenati, F., and Battistini, N. (1983b). Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites. Acta Physiol. Scand. 119, 459–461. doi: 10.1111/j.1748-1716.1983.tb07363.x
3. Agnati, L. F., Guidolin, D., Guescini, M., Genedani, S., and Fuxe, K. (2010). Understanding wiring and volume transmission. Brain Res. Rev. 64, 137–159. doi: 10.1016/j.brainresrev.2010.03.003
4. 2receptors. Neuropharmacology 61, 770–777. doi: 10.1016/j.neuropharm. 2011.05.023
5. Amargós-Bosch, M., Bortolozzi, A., Puig, M. V., Serrats, J., Adell, A., Celada, P., et al. (2004). Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb. Cortex 14, 281–299. doi: 10.1093/cercor/bhg128
6. Andén, N. E., Dahlström, A., Fuxe, K., Olson, L., and Ungerstedt, U. (1966). Ascending monoamine neurons to the telencephalon and diencephalon. Acta Physiol. Scand. 67, 313–326. doi: 10.1111/j.1748-1716.1966. tb03318.x
7. Artigas, F. (2013). Serotonin receptors involved in antidepressant effects. Pharmacol. Ther. 137, 119–131. doi: 10.1016/j.pharmthera.2012. 09.006
8. Artigas, F. (2014). Deep brain stimulation in major depression: plastic changes of 5-hydroxytryptamine neurons. Biol. Psychiatry 76, 174–175. doi: 10.1016/j. biopsych.2014.05.008
9. Artigas, F. (2015). Developments in the field of antidepressants, where do we go now? Eur. Neuropsychopharmacol. 25, 657–670. doi: 10.1016/j.euroneuro.2013. 04.013
10. Bailey, A., Metaxas, A., Yoo, J. H., McGee, T., and Kitchen, I. (2008). Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose ‘binge’ cocaine administration paradigm. Eur. J. Neurosci. 28, 759–770. doi: 10.1111/j.1460-9568.2008. 06369.x
11. Balu, D. T. (2016). The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv. Pharmacol. 76, 351–382. doi: 10.1016/bs.apha.2016.01.006
12. Barnes, N. M., and Sharp, T. (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083–1152. doi: 10.1016/s0028-3908(99)00010-6
13. Bellido, I., Diaz-Cabiale, Z., Jiménez-Vasquez, P. A., Andbjer, B., Mathé, A. A., and Fuxe, K. (2002). Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci. Lett. 317, 101–105. doi: 10.1016/s0304-3940(01)02446-6
14. Borroto-Escuela, D. O., Agnati, L. F., Bechter, K., Jansson, A., Tarakanov, A. O., and Fuxe, K. (2015a). The role of transmitter diffusion and flow versus extracellular vesicles in volume transmission in the brain neural-glial networks. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370:20140183. doi: 10.1098/rstb.2014. 0183
15. Borroto-Escuela, D. O., Brito, I., Di Palma, M., Jiménez-Beristain, A., Narvaéz, M., Corrales, F., et al. (2015b). On the role of the balance of GPCR homo/ heteroreceptor complexes in the brain. J. Adv. Neurosci. Res. 2, 36–44. doi: 10.15379/2409-3564.2015.02.01.5
16. Borroto-Escuela, D. O., Narvaez, M., Pérez-Alea, M., Tarakanov, A. O., Jimenéz-Beristain, A., Mudó, G., et al. (2015c). Evidence for the existence of FGFR1–5-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system. Biochem. Biophys. Res. Commun. 456, 489–493. doi: 10.1016/j.bbrc.2014.11.112
17. Borroto-Escuela, D. O., Pérez-Alea, M., Narvaez, M., Tarakanov, A. O., Mudó, G., Jiménez-Beristain, A., et al. (2015d). Enhancement of the FGFR1 signaling in the FGFR1–5-HT1A heteroreceptor complex in midbrain raphe 5-HT neuron systems. Relevance for neuroplasticity and depression. Biochem. Biophys. Res. Commun. 463, 180–186. doi: 10.1016/j.bbrc.2015.04.133
18. Borroto-Escuela, D. O., Wydra, K., Ferraro, L., Rivera, A., Filip, M., and Fuxe, K. (2015e). ‘‘Role of D2-like heteroreceptor compelxes in the effects of cocaine, morphine and hallucinogens,’’ in Neurophatology of Drug Addictions and Substance Misuse, ed. V. Preedy (London: Elsevier), 93–101.
19. Borroto-Escuela, D. O., Agnati, L. F., Fuxe, K., and Ciruela, F. (2012a). Muscarinic acetylcholine receptor-interacting proteins (mAChRIPs): targeting the receptorsome. Curr. Drug. Targets 13, 53–71. doi: 10.2174/138945012798868506
20. Borroto-Escuela, D. O., Romero-Fernandez, W., Mudó, G., Pérez-Alea, M., Ciruela, F., Tarakanov, A. O., et al. (2012b). Fibroblast growth factor receptor 1- 5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity. Biol. Psychiatry 71, 84–91. doi: 10.1016/j.biopsych.2011.09.012
21. Borroto-Escuela, D. O., Brito, I., Romero-Fernandez, W., Di Palma, M., Oflijan, J., Skieterska, K., et al. (2014a). The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components. Int. J. Mol. Sci. 15, 8570–8590. doi: 10.3390/ijms15058570
22. Borroto-Escuela, D. O., Narvaez, M., Di Palma, M., Calvo, F., Rodriguez, D., Millon, C., et al. (2014b). Preferential activation by galanin 1–15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex. Biochem. Biophys. Res. Commun. 452, 347–353. doi: 10.1016/j.bbrc.2014.08.061
23. Borroto-Escuela, D. O., Romero-Fernandez, W., Narvaez, M., Oflijan, J., Agnati, L. F., and Fuxe, K. (2014c). Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2–5-HT2A heteroreceptor complexes. Biochem. Biophys. Res. Commun. 443, 278–284. doi: 10.1016/j.bbrc.2013.11.104
24. Borroto-Escuela, D. O., Corrales, F., Narvaez, M., Oflijan, J., Agnati, L. F., Palkovits, M., et al. (2013a). Dynamic modulation of FGFR1–5-HT1A heteroreceptor complexes. Agonist treatment enhances participation of FGFR1 and 5-HT1A homodimers and recruitment of β-arrestin2. Biochem. Biophys. Res. Commun. 441, 387–392. doi: 10.1016/j.bbrc.2013.10.067
25. Borroto-Escuela, D. O., Ravani, A., Tarakanov, A. O., Brito, I., Narvaez, M., Romero-Fernandez, W., et al. (2013b). Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem. Biophys. Res. Commun. 435, 140–146. doi: 10.1016/j.bbrc.2013. 04.058
26. Borroto-Escuela, D. O., Romero-Fernandez, W., Garriga, P., Ciruela, F., Narvaez, M., Tarakanov, A. O., et al. (2013c). G protein-coupled receptor heterodimerization in the brain. Methods Enzymol. 521, 281–294. doi: 10.1016/B978-0-12-391862-8.00015-6
27. Borroto-Escuela, D. O., Hagman, B., Woolfenden, M., Pinton, L., Jiménez-Beristain, A., Oflijan, J., et al. (2016a). ‘‘In situ proximity ligation assay to study and understand the distribution and balance of GPCR homo- and heteroreceptor complexes in the brain,’’ in Receptor and Ion Channel Detection in the Brain, eds R. Lujan and F. Ciruela (Berlin: Springer), 109–126.
28. Borroto-Escuela, D. O., Narváez, M., Jiménez-Beristain, A., and Fuxe, K. (2016b). ‘‘FGFR1–5-HT1A heteroreceptor complexes in the hippocampus and midbrain raphe as a novel target for antidepressant drugs,’’ in 30th CINP World Congress of Neuropsychopharmacology, (Seoul, Republic of Korea: CINP).
29. Borroto-Escuela, D. O., Tarakanov, A. O., and Fuxe, K. (2016c). FGFR1–5-HT1A heteroreceptor complexes: implications for understanding and treating major depression. Trends Neurosci. 39, 5–15. doi: 10.1016/j.tins.2015.11.003
30. Borroto-Escuela, D. O., Wydra, K., Pintsuk, J., Narvaez, M., Corrales, F., Zaniewska, M., et al. (2016d). Understanding the functional plasticity in neural networks of the basal ganglia in cocaine use disorder: a role for allosteric receptor–receptor interactions in A2A-D2 heteroreceptor complexes. Neural Plast. 2016:4827268. doi: 10.1155/2016/4827268
31. Borroto-Escuela, D. O., Marcellino, D., Narvaez, M., Flajolet, M., Heintz, N., Agnati, L., et al. (2010a). A serine point mutation in the adenosine A2AR C-terminal tail reduces receptor heteromerization and allosteric modulation of the dopamine D2R. Biochem. Biophys. Res. Commun. 394, 222–227. doi: 10.1016/j.bbrc.2010.02.168
32. Borroto-Escuela, D. O., Narvaez, M., Marcellino, D., Parrado, C., Narvaez, J. A., Tarakanov, A. O., et al. (2010b). Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization. Biochem. Biophys. Res. Commun. 393, 767–772. doi: 10.1016/j.bbrc.2010.02.078
33. Borroto-Escuela, D. O., Romero-Fernandez, W., Tarakanov, A. O., Gómez-Soler, M., Corrales, F., Marcellino, D., et al. (2010c). Characterization of the A2AR-D2R interface: focus on the role of the C-terminal tail and the transmembrane helices. Biochem. Biophys. Res. Commun. 402, 801–807. doi: 10.1016/j.bbrc.2010.10.122
34. 2Areceptors assemble into functionally interacting heteromers. Biochem. Biophys. Res. Commun. 401, 605–610. doi: 10.1016/j.bbrc.2010.09.110
35. Borroto-Escuela, D. O., Van Craenenbroeck, K., Romero-Fernandez, W., Guidolin, D., Woods, A. S., Rivera, A., et al. (2010e). Dopamine D2 and D4 receptor heteromerization and its allosteric receptor–receptor interactions. Biochem. Biophys. Res. Commun. 404, 928–934. doi: 10.1016/j.bbrc.2010. 12.083
36. Borroto-Escuela, D. O., Tarakanov, A. O., Guidolin, D., Ciruela, F., Agnati, L. F., and Fuxe, K. (2011). Moonlighting characteristics of G protein-coupled receptors: focus on receptor heteromers and relevance for neurodegeneration. IUBMB Life 63, 463–472. doi: 10.1002/iub.473
37. Branchek, T., Smith, K. E., and Walker, M. W. (1998). Molecular biology and pharmacology of galanin receptors. Ann. N Y Acad. Sci. 863, 94–107. doi: 10.1111/j.1749-6632.1998.tb10687.x
38. Briand, L. A., Flagel, S. B., Garcia-Fuster, M. J., Watson, S. J., Akil, H., Sarter, M., et al. (2008). Persistent alterations in cognitive function and prefrontal dopamine D2 receptors following extended, but not limited, access to self-administered cocaine. Neuropsychopharmacology 33, 2969–2980. doi: 10.1038/npp.2008.18
39. Cabello, N., Gandia, J., Bertarelli, D. C., Watanabe, M., Lluís, C., Franco, R., et al. (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J. Neurochem. 109, 1497–1507. doi: 10.1111/j.1471-4159.2009.06078.x
40. Caldwell, H. K., Stephens, S. L., and Young, W. S. III. (2009). Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol. Psychiatry 14, 190–196. doi: 10.1038/sj.mp.4002150
41. Carlsson, A., Fuxe, K., and Ungerstedt, U. (1968). The effect of imipramine on central 5-hydroxytryptamine neurons. J. Pharm. Pharmacol. 20, 150–151. doi: 10.1111/j.2042-7158.1968.tb09706.x
42. Celada, P., Bortolozzi, A., and Artigas, F. (2013). Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27, 703–716. doi: 10.1007/s40263-013-0071-0
43. 2Areceptors in depression. J. Psychiatry Neurosci. 29, 252–265.
44. Coppen, A. (1967). The biochemistry of affective disorders. Br. J. Psychiatry 113, 1237–1264. doi: 10.1192/bjp.113.504.1237
45. Dahlstroem, A., and Fuxe, K. (1964). Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. Suppl. 232, 1–55.
46. 1opioid receptor phenotypes. J. Med. Chem. 48, 1713–1716. doi: 10.1021/jm034234f
47. de Bartolomeis, A., Buonaguro, E. F., and Iasevoli, F. (2013). Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology 225, 1–19. doi: 10.1007/s00213-012-2921-8
48. de la Mora, M. P., Pérez-Carrera, D., Crespo-Ramírez, M., Tarakanov, A., Fuxe, K., and Borroto-Escuela, D. O. (2016). Signaling in dopamine D2 receptor-Oxytocin receptor heterocomplexes and its relevance for the anxiolytic effects of dopamine and oxytocin interactions in the amygdala of the rat. Biochim. Biophys. Acta 1862, 2075–2085. doi: 10.1016/j.bbadis.2016. 07.004
49. Di Liberto, V., Borroto-Escuela, D. O., Frinchi, M., Verdi, V., Fuxe, K., Belluardo, N., et al. (2017). Existence of muscarinic acetylcholine receptor (mAChR) and fibroblast growth factor receptor (FGFR) heteroreceptor complexes and their enhancement of neurite outgrowth in neural hippocampal cultures. Biochim. Biophys. Acta 1861, 235–245. doi: 10.1016/j.bbagen.2016.10.026
50. Dunham, J. H., Meyer, R. C., Garcia, E. L., and Hall, R. A. (2009). GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions. PLoS One 48, 10286–10297. doi: 10.1021/bi9013775
51. Edwards, S., Whisler, K. N., Fuller, D. C., Orsulak, P. J., and Self, D. W. (2007). Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. Neuropsychopharmacology 32, 354–366. doi: 10.1038/sj.npp.1301062
52. Espinoza, S., Salahpour, A., Masri, B., Sotnikova, T. D., Messa, M., Barak, L. S., et al. (2011). Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol. Pharmacol. 80, 416–425. doi: 10.1124/mol.111.073304
53. Feifel, D. (2012). Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions. Neuropsychopharmacology 37, 304–305. doi: 10.1038/npp.2011.184
54. Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., et al. (2010). Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 68, 678–680. doi: 10.1016/j.biopsych.2010.04.039
55. Ferraro, L., Beggiato, S., Borroto-Escuela, D. O., Ravani, L., O’Connor, W. T., Tomasini, M. C., et al. (2014). Neurotensin NTS1-dopamine D2 receptor–receptor interactions in putative receptor heteromers: relevance for Parkinson’s disease and schizophrenia. Curr. Protein Pept. Sci. 15, 681–690. doi: 10.2174/1389203715666140901105253
56. Ferraro, L., O’Connor, W. T., Beggiato, S., Tomasini, M. C., Fuxe, K., Tanganelli, S., et al. (2012). Striatal NTS1, dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release–a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat. Eur. J. Neurosci. 35, 207–220. doi: 10.1111/j.1460-9568.2011.07949.x
57. Ferraro, L., Tomasini, M. C., Mazza, R., Fuxe, K., Fournier, J., Tanganelli, S., et al. (2008). Neurotensin receptors as modulators of glutamatergic transmission. Brain Res. Rev. 58, 365–373. doi: 10.1016/j.brainresrev.2007.11.001
58. Ferré, S., Karcz-Kubicha, M., Hope, B. T., Popoli, P., Burgueño, J., Gutiérrez, M. A., et al. (2002). Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. U S A 99, 11940–11945. doi: 10.1073/pnas.172393799
59. Filip, M., Frankowska, M., Zaniewska, M., Przegalinski, E., Muller, C. E., Agnati, L., et al. (2006). Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 1077, 67–80. doi: 10.1016/j.brainres.2006.01.038
60. 2receptor interaction in drug addiction. Curr. Med. Chem. 19, 317–355. doi: 10.2174/092986712803414231
61. 2Areceptor to regulate synaptic plasticity. Nat. Neurosci. 11, 1402–1409. doi: 10.1038/nn.2216
62. Frankowska, M., Marcellino, D., Adamczyk, P., Filip, M., and Fuxe, K. (2013). Effects of cocaine self-administration and extinction on D2 -like and A2A receptor recognition and D2 -like/Gi protein coupling in rat striatum. Addict. Biol. 18, 455–466. doi: 10.1111/j.1369-1600.2012.00452.x
63. Fuxe, K. (1965). Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monoamine nerve terminals in the central nervous system. Acta Physiol. Scand. Suppl. 247, 39–85.
64. Fuxe, K., and Agnati, L. F. (1985). Receptor–receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 5, 441–482. doi: 10.1002/med.2610050404
65. Fuxe, K., Agnati, L. F., Benfenati, F., Celani, M., Zini, I., Zoli, M., et al. (1983). Evidence for the existence of receptor–receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J. Neural Transm. Suppl. 18, 165–179.
66. Fuxe, K., Agnati, L. F., and Borroto-Escuela, D. O. (2014a). The impact of receptor–receptor interactions in heteroreceptor complexes on brain plasticity. Expert Rev. Neurother. 14, 719–721. doi: 10.1586/14737175.2014. 922878
67. Fuxe, K., Borroto-Escuela, D. O., Ciruela, F., Guidolin, D., and Agnati, L. F. (2014b). Receptor–receptor interactions in heteroreceptor complexes: a new principle in biology. Focus on their role in learning and memory. Neurosci. Discov. 2:6. doi: 10.7243/2052-6946-2-6
68. Fuxe, K., Borroto-Escuela, D. O., Fisone, G., Agnati, L. F., and Tanganelli, S. (2014c). Understanding the role of heteroreceptor complexes in the central nervous system. Curr. Protein Pept. Sci. 15:647. doi: 10.2174/138920371507140916122738
69. Fuxe, K., Borroto-Escuela, D. O., Romero-Fernandez, W., Palkovits, M., Tarakanov, A. O., Ciruela, F., et al. (2014d). Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field. Neuropsychopharmacology 39, 131–155. doi: 10.1038/npp.2013.242
70. Fuxe, K., Borroto-Escuela, D. O., Tarakanov, A. O., Romero-Fernandez, W., Ferraro, L., Tanganelli, S., et al. (2014e). Dopamine D2 heteroreceptor complexes and their receptor–receptor interactions in ventral striatum: novel targets for antipsychotic drugs. Prog. Brain Res. 211, 113–139. doi: 10.1016/B978-0-444-63425-2.00005-2
71. Fuxe, K., Tarakanov, A., Romero-Fernandez, W., Ferraro, L., Tanganelli, S., Filip, M., et al. (2014f). Diversity and bias through receptor–receptor interactions in GPCR heteroreceptor complexes. Focus on examples from dopamine D2 receptor heteromerization. Front. Endocrinol. 5:71. doi: 10.3389/fendo.2014.00071
72. Fuxe, K., Agnati, L. F., Jacobsen, K., Hillion, J., Canals, M., Torvinen, M., et al. (2003). Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson’s disease. Neurology 61, S19–S23. doi: 10.1212/01.WNL.0000095206.44418.5c
73. Fuxe, K., Agnati, L. F., and Mora, F. (2008a). The basal ganglia-from neuronal systems to molecular networks. Preface. Brain Res. Rev. 58, 247–248. doi: 10.1016/j.brainresrev.2008.05.002
74. Fuxe, K., Marcellino, D., Guidolin, D., Woods, A. S., and Agnati, L. F. (2008b). Heterodimers and receptor mosaics of different types of G-protein-coupled receptors. Physiology 23, 322–332. doi: 10.1152/physiol.00028.2008
75. Fuxe, K., Marcellino, D., Rivera, A., Diaz-Cabiale, Z., Filip, M., Gago, B., et al. (2008c). Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev. 58, 415–452. doi: 10.1016/j.brainresrev.2007.11.007
76. Fuxe, K., and Borroto-Escuela, D. O. (2015). Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin. Investig. Drugs 24, 1247–1260. doi: 10.1517/13543784.2015.1074175
77. Fuxe, K., and Borroto-Escuela, D. O. (2016). Heteroreceptor complexes and their allosteric receptor–receptor interactions as a novel biological principle for integration of communication in the cns: targets for drug development. Neuropsychopharmacology 41, 380–382. doi: 10.1038/npp.2015.244
78. Fuxe, K., Borroto-Escuela, D. O., Marcellino, D., Romero-Fernandez, W., Frankowska, M., Guidolin, D., et al. (2012a). GPCR heteromers and their allosteric receptor–receptor interactions. Curr. Med. Chem. 19, 356–363. doi: 10.2174/092986712803414259
79. Fuxe, K., Borroto-Escuela, D. O., Romero-Fernandez, W., Ciruela, F., Manger, P., Leo, G., et al. (2012b). On the role of volume transmission and receptor–receptor interactions in social behaviour: focus on central catecholamine and oxytocin neurons. Brain Res. 1476, 119–131. doi: 10.1016/j. brainres.2012.01.062
80. Fuxe, K., Borroto-Escuela, D. O., Romero-Fernandez, W., Tarakanov, A. O., Calvo, F., Garriga, P., et al. (2012c). On the existence and function of galanin receptor heteromers in the central nervous system. Front. Endocrinol. 3:127. doi: 10.3389/fendo.2012.00127
81. Fuxe, K., and Dahlström, A. (2009). Evidence for the Existence of Central Monoamine Neurons. (Saarbrucken, Germany: VDM Verlag).
82. Fuxe, K., Dahlström, A., Höistad, M., Marcellino, D., Jansson, A., Rivera, A., et al. (2007). From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission. Brain Res. Rev. 55, 17–54. doi: 10.1016/j.brainresrev.2007.02.009
83. Fuxe, K., Dahlström, A. B., Jonsson, G., Marcellino, D., Guescini, M., Dam, M., et al. (2010a). The discovery of central monoamine neurons gave volume transmission to the wired brain. Prog. Neurobiol. 90, 82–100. doi: 10.1016/j.pneurobio.2009.10.012
84. Fuxe, K., Marcellino, D., Borroto-Escuela, D. O., Guescini, M., Fernández-Dueñas, V., Tanganelli, S., et al. (2010b). Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e18–e42. doi: 10.1111/j.1755-5949.2009.00126.x
85. Fuxe, K., Ferré, S., Zoli, M., and Agnati, L. F. (1998). Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. 26, 258–273. doi: 10.1016/s0165-0173(97)00049-0
86. Fuxe, K., Guidolin, D., Agnati, L. F., and Borroto-Escuela, D. O. (2015). Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease. Expert Opin. Ther. Targets 19, 377–398. doi: 10.1517/14728222.2014.981529
87. Fuxe, K., Hedlund, P., von Euler, G., Lundgren, K., Martire, M., Ogren, S. O., et al. (1991). ‘‘Galanin/5-HT interactions in the rat central nervous system. Relevance for depression,’’ in Galanin: A New Multifunctional Peptide in the Neuroendocrine System, eds T. Hokfelt, T. Bartfai, D. M. Jacobowitz and D. Ottoson (London: MacMillan Press), 221–235.
88. Fuxe, K., Ogren, S. O., Agnati, L., Gustafsson, J. A., and Jonsson, G. (1977). On the mechanism of action of the antidepressant drugs amitriptyline and nortriptyline. Evidence for 5-hydroxytryptamine receptor blocking activity. Neurosci. Lett. 6, 339–343. doi: 10.1016/0304-3940(77) 90095-7
89. Fuxe, K., and Ungerstedt, U. (1967). Localization of 5-hydroxytryptamine uptake in rat brain after intraventricular injection. J. Pharm. Pharmacol. 19, 335–337. doi: 10.1111/j.2042-7158.1967.tb08097.x
90. Fuxe, K., von Euler, G., Agnati, L. F., and Ogren, S. O. (1988). Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci. Lett. 85, 163–167. doi: 10.1016/0304-3940(88) 90448-x
91. George, S. R., O’Dowd, B. F., and Lee, S. P. (2002). G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov. 1, 808–820. doi: 10.1038/nrd913
92. Gingrich, B., Liu, Y., Cascio, C., Wang, Z., and Insel, T. R. (2000). Dopamine D2 receptors in the nucleus accumbens are important for social attachment in female prairie voles (Microtus ochrogaster). Behav. Neurosci. 114, 173–183. doi: 10.1037/0735-7044.114.1.173
93. Ginovart, N., and Kapur, S. (2010). ‘‘Dopamine receptors and the treatment of schizophrenia,’’ in The Dopamine Receptor, ed. K. A. Neve (Portland: Humana Press), 431–478.
94. 1Areceptor. Mol. Pharmacol. 82, 448–463. doi: 10.1124/mol.112.079137
95. Grace, A. A. (2017). Dopamine system dysregulation and the pathophysiology of schizophrenia: insights from the methylazoxymethanol acetate model. Biol. Psychiatry 81, 5–8. doi: 10.1016/j.biopsych.2015.11.007
96. Guidolin, D., Agnati, L. F., Marcoli, M., Borroto-Escuela, D. O., and Fuxe, K. (2015). G-protein-coupled receptor type A heteromers as an emerging therapeutic target. Expert Opin. Ther. Targets 19, 265–283. doi: 10.1517/14728222.2014.981155
97. Guo, W., Urizar, E., Kralikova, M., Mobarec, J. C., Shi, L., Filizola, M., et al. (2008). Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J. 27, 2293–2304. doi: 10.1038/emboj.2008.153
98. Gutiérrez-de-Terán, H., Sallander, J., and Sotelo, E. (2017). Structure-based rational design of adenosine receptor ligands. Curr. Top. Med. Chem. 17, 40–58. doi: 10.2174/1568026616666160719164207
99. Han, Y., Moreira, I. S., Urizar, E., Weinstein, H., and Javitch, J. A. (2009). Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat. Chem. Biol. 5, 688–695. doi: 10.1038/nchembio.199
100. 2+signaling and cell survival. Cell 131, 596–610. doi: 10.1016/j.cell.2007.08.036
101. Hedlund, P. B., Finnman, U. B., Yanaihara, N., and Fuxe, K. (1994). Galanin-(1–15), but not galanin-(1–29), modulates 5-HT1A receptors in the dorsal hippocampus of the rat brain: possible existence of galanin receptor subtypes. Brain Res. 634, 163–167. doi: 10.1016/0006-8993(94)90271-2
102. Hedlund, P. B., Yanaihara, N., and Fuxe, K. (1992). Evidence for specific N-terminal galanin fragment binding sites in the rat brain. Eur. J. Pharmacol. 224, 203–205. doi: 10.1016/0014-2999(92)90806-f
103. Hillion, J., Canals, M., Torvinen, M., Casado, V., Scott, R., Terasmaa, A., et al. (2002). Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091–18097. doi: 10.1074/jbc.M107731200
104. Holst, B., Egerod, K. L., Schild, E., Vickers, S. P., Cheetham, S., Gerlach, L. O., et al. (2007). GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148, 13–20. doi: 10.1210/en.2006-0933
105. Huber, D., Löber, S., Hübner, H., and Gmeiner, P. (2012). Bivalent molecular probes for dopamine D2-like receptors. Bioorg. Med. Chem. 20, 455–466. doi: 10.1016/j.bmc.2011.10.063
106. Hübner, H., Schellhorn, T., Gienger, M., Schaab, C., Kaindl, J., Leeb, L., et al. (2016). Structure-guided development of heterodimer-selective GPCR ligands. Nat. Commun. 7:12298. doi: 10.1038/ncomms12298
107. Insel, T. R., and Young, L. J. (2001). The neurobiology of attachment. Nat. Rev. Neurosci. 2, 129–136. doi: 10.1038/35053579
108. Kapur, S. (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology and pharmacology in schizophrenia. Am. J. Psychiatry 160, 13–23. doi: 10.1176/appi.ajp.160.1.13
109. Kenakin, T. (2007). Functional selectivity through protean and biased agonism: who steers the ship? Mol. Pharmacol. 72, 1393–1401. doi: 10.1124/mol.107. 040352
110. Kenakin, T. P. (2008). Seven transmembrane receptors as nature’s prototype allosteric protein: de-emphasizing the geography of binding. Mol. Pharmacol. 74, 541–543. doi: 10.1124/mol.108.050062
111. Kenakin, T. (2011). Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296–302. doi: 10.1124/jpet.110.173948
112. Kern, A., Albarran-Zeckler, R., Walsh, H. E., and Smith, R. G. (2012). Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73, 317–332. doi: 10.1016/j.neuron.2011.10.038
113. Koschatzky, S., Tschammer, N., and Gmeiner, P. (2011). Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics. ACS Chem. Neurosci. 2, 308–316. doi: 10.1021/cn200020y
114. Kourrich, S., Hayashi, T., Chuang, J. Y., Tsai, S. Y., Su, T. P., and Bonci, A. (2013). Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine. Cell 152, 236–247. doi: 10.1016/j.cell.2012. 12.004
115. Le Naour, M., Akgün, E., Yekkirala, A., Lunzer, M. M., Powers, M. D., Kalyuzhny, A. E., et al. (2013). Bivalent ligands that target mu opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. J. Med. Chem. 56, 5505–5513. doi: 10.1021/jm4005219
116. Liebmann, T., Renier, N., Bettayeb, K., Greengard, P., Tessier-Lavigne, M., and Flajolet, M. (2016). Three-dimensional study of Alzheimer’s disease hallmarks using the idisco clearing method. Cell Rep. 16, 1138–1152. doi: 10.1016/j.celrep. 2016.06.060
117. Liu, X. Y., Chu, X. P., Mao, L. M., Wang, M., Lan, H. X., Li, M. H., et al. (2006). Modulation of D2R-NR2B interactions in response to cocaine. Neuron 52, 897–909. doi: 10.1016/j.neuron.2006.10.011
118. Liu, F., Wan, Q., Pristupa, Z. B., Yu, X. M., Wang, Y. T., and Niznik, H. B. (2000). Direct protein-protein coupling enables cross-talk between dopamine D5 and γ-aminobutyric acid A receptors. Nature 403, 274–280. doi: 10.1038/35002014
119. Lu, X., Ross, B., Sanchez-Alavez, M., Zorrilla, E. P., and Bartfai, T. (2008). Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests. Neuropeptides 42, 387–397. doi: 10.1016/j.npep.2008.04.009
120. Maudsley, S., Martin, B., and Luttrell, L. M. (2005). The origins of diversity and specificity in g protein-coupled receptor signaling. J. Pharmacol. Exp. Ther. 314, 485–494. doi: 10.1124/jpet.105.083121
121. Maurice, T., and Su, T. P. (2009). The pharmacology of sigma-1 receptors. Pharmacol. Ther. 124, 195–206. doi: 10.1016/j.pharmthera.2009.07.001
122. 2Ainverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease. Behav. Pharmacol. 22, 681–692. doi: 10.1097/FBP. 0b013e32834aff98
123. Meltzer, H. Y., Matsubara, S., and Lee, J. C. (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238–246.
124. Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., et al. (2010). Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology 35, 881–892. doi: 10.1038/npp.2009.176
125. Migues, P. V., Liu, L., Archbold, G. E., Einarsson, E. O., Wong, J., Bonasia, K., et al. (2016). Blocking synaptic removal of GluA2-containing AMPA receptors prevents the natural forgetting of long-term memories. J. Neurosci. 36, 3481–3494. doi: 10.1523/JNEUROSCI.3333-15.2016
126. Milosevic, A., Liebmann, T., Knudsen, M., Schintu, N., Svenningsson, P., and Greengard, P. (2017). Cell- and region-specific expression of depression-related protein p11 (S100a10) in the brain. J. Comp. Neurol. 525, 955–975. doi: 10.1002/cne.24113
127. Millón, C., Flores-Burgess, A., Narváez, M., Borroto-Escuela, D. O., Santín, L., Gago, B., et al. (2016). Galanin (1–15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT. Involvement of the raphe-hippocampal 5-HT neuron system. Brain Struct. Funct. 221, 4491–4504. doi: 10.1007/s00429-015-1180-y
128. Millón, C., Flores-Burgess, A., Narvaez, M., Borroto-Escuela, D. O., Santin, L., Parrado, C., et al. (2014). A role for galanin N-terminal fragment (1–15) in anxiety- and depression-related behaviors in rats. Int. J. Neuropsychopharmacol. 18:3. doi: 10.1093/ijnp/pyu064
129. Młyniec, K., Budziszewska, B., Reczynski, W., Sowa-Kucma, M., and Nowak, G. (2013). The role of the GPR39 receptor in zinc deficient-animal model of depression. Behav. Brain Res. 238, 30–35. doi: 10.1016/j.bbr.2012.10.020
130. Młyniec, K., Gawel, M., and Nowak, G. (2015). Study of antidepressant drugs in GPR39 (zinc receptor(-)/(-)) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists. Behav. Brain Res. 287, 135–138. doi: 10.1016/j.bbr.2015.03.053
131. Navarro, G., Moreno, E., Aymerich, M., Marcellino, D., McCormick, P. J., Mallol, J., et al. (2010). Direct involvement of sigma-1 receptors in the dopamine D1 receptor-mediated effects of cocaine. Proc. Natl. Acad. Sci. U S A 107, 18676–18681. doi: 10.1073/pnas.1008911107
132. Navarro, G., Moreno, E., Bonaventura, J., Brugarolas, M., Farré, D., Aguinaga, D., et al. (2013). Cocaine inhibits dopamine D2 receptor signaling via sigma-1–D2 receptor heteromers. PLoS One 8:e61245. doi: 10.1371/journal.pone.0061245
133. Ogren, S. O., Fuxe, K., Agnati, L. F., Gustafsson, J. A., Jonsson, G., and Holm, A. C. (1979). Reevaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5-HT systems by antidepressant drugs. J. Neural Transm. 46, 85–103. doi: 10.1007/bf01250331
134. Peroutka, S. J., and Snyder, S. H. (1979). Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol. Pharmacol. 16, 687–699.
135. Pinton, L., Borroto-Escuela, D. O., Narváez, M., Jiménez-Beristain, A., Oflijan, J., Ferraro, L., et al. (2015a). ‘‘Dopamine D2 receptor dynamic and modulation in the D2R-Sigma1R heteroreceptor complexes: role in cocaine actions,’’ in European Neuropsychopharmacology, (Amsterdam: Elsevier), S609–S610.
136. Pinton, L., Borroto-Escuela, D. O., Narváez, M., Oflijan, J., Agnati, L. F., and Fuxe, K. (2015b). Evidence for the existence of dopamine D2R and Sigma 1 allosteric receptor–receptor interaction in the rat brain: role in brain plasticity and cocaine action. Springerplus 4:P37. doi: 10.1186/2193-1801-4-s1-p37
137. Pintsuk, J., Borroto-Escuela, D. O., Lai, T. K., Liu, F., and Fuxe, K. (2016a). Alterations in ventral and dorsal striatal allosteric A2AR-D2R receptor–receptor interactions after amphetamine challenge: relevance for schizophrenia. Life Sci. doi: 10.1016/j.lfs.2016.10.027 [Epub ahead of print].
138. Pintsuk, J., Borroto-Escuela, D. O., Pomierny, B., Wydra, K., Zaniewska, M., Filip, M., et al. (2016b). Cocaine self-administration differentially affects allosteric A2A-D2 receptor–receptor interactions in the striatum. Relevance for cocaine use disorder. Pharmacol. Biochem. Behav. 144, 85–91. doi: 10.1016/j. pbb.2016.03.004
139. Portoghese, P. S. (2001). From models to molecules: opioid receptor dimers, bivalent ligands and selective opioid receptor probes. J. Med. Chem. 44, 2259–2269. doi: 10.1021/jm010158+
140. Przybyla, J. A., and Watts, V. J. (2010). Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J. Pharmacol. Exp. Ther. 332, 710–719. doi: 10.1124/jpet.109.162701
141. Renner, U., Zeug, A., Woehler, A., Niebert, M., Dityatev, A., Dityateva, G., et al. (2012). Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J. Cell Sci. 125, 2486–2499. doi: 10.1242/jcs.101337
142. Rimondini, R., Ferré, S., Ogren, S. O., and Fuxe, K. (1997). Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17, 82–91. doi: 10.1016/S0893-133X(97) 00033-X
143. Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., and Patel, Y. C. (2000). Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154–157. doi: 10.1126/science.288.5463.154
144. Romero-Fernandez, W., Borroto-Escuela, D. O., Agnati, L. F., and Fuxe, K. (2013). Evidence for the existence of dopamine D2-oxytocin receptor heteromers in the ventral and dorsal striatum with facilitatory receptor–receptor interactions. Mol. Psychiatry 18, 849–850. doi: 10.1038/mp.2012.103
145. 1receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26, 444–455. doi: 10.1016/s0893-133X(01)00391-8
146. Salim, K., Fenton, T., Bacha, J., Urien-Rodriguez, H., Bonnert, T., Skynner, H. A., et al. (2002). Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J. Biol. Chem. 277, 15482–15485. doi: 10.1074/jbc.M201539200
147. Scarselli, M., Novi, F., Schallmach, E., Lin, R., Baragli, A., Colzi, A., et al. (2001). D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276, 30308–30314. doi: 10.1074/jbc.M102297200
148. Schintu, N., Zhang, X., Alvarsson, A., Marongiu, R., Kaplitt, M. G., Greengard, P., et al. (2016). p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proc. Natl. Acad. Sci. U S A 113, 1429–1434. doi: 10.1073/pnas.1524303113
149. Seeman, P. (2010). Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4, 56–73. doi: 10.3371/CSRP.4.1.5
150. Seeman, P., Tallerico, T., Ko, F., Tenn, C., and Kapur, S. (2002). Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46, 235–239. doi: 10.1002/syn.10139
151. Self, D. W. (2010). ‘‘Dopamine receptor subtypes in reward and relapse,’’ in The Dopamine Receptors, ed. K. A. Neve (Portland: Humana Press), 479–524.
152. So, C. H., Verma, V., Alijaniaram, M., Cheng, R., Rashid, A. J., O’Dowd, B. F., et al. (2009). Calcium signaling by dopamine D5 receptor and D5–D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1–D2 receptor hetero-oligomers. Mol. Pharmacol. 75, 843–854. doi: 10.1124/mol.108.051805
153. Soriano, A., Ventura, R., Molero, A., Hoen, R., Casadó, V., Cortés, A., et al. (2009). Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med. Chem. 52, 5590–5602. doi: 10.1021/jm900298c
154. Su, P., Li, S., Chen, S., Lipina, T. V., Wang, M., Lai, T. K., et al. (2014). A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects. Neuron 84, 1302–1316. doi: 10.1016/j.neuron.2014.11.007
155. Svenningsson, P. (2014). Reductions of p11 and 5-HT1B receptor availability in limbic brain regions in cocaine dependence. Biol. Psychiatry 76, 763–764. doi: 10.1016/j.biopsych.2014.08.011
156. Svenningsson, P., Kim, Y., Warner-Schmidt, J., Oh, Y. S., and Greengard, P. (2013). p11 and its role in depression and therapeutic responses to antidepressants. Nat. Rev. Neurosci. 14, 673–680. doi: 10.1038/nrn3564
157. Tanganelli, S., Antonelli, T., Tomasini, M. C., Beggiato, S., Fuxe, K., and Ferraro, L. (2012). Relevance of dopamine D2/neurotensin NTS1 and NMDA/neurotensin NTS1 receptor interaction in psychiatric and neurodegenerative disorders. Curr. Med. Chem. 19, 304–316. doi: 10.2174/092986712803414268
158. Tanganelli, S., Sandager Nielsen, K., Ferraro, L., Antonelli, T., Kehr, J., Franco, R., et al. (2004). Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson’s Disease. Parkinsonism Relat. Disord. 10, 273–280. doi: 10.1016/j.parkreldis.2004.02.015
159. Tarakanov, A. O., and Fuxe, K. G. (2010). Triplet puzzle: homologies of receptor heteromers. J. Mol. Neurosci. 41, 294–303. doi: 10.1007/s12031-009-9313-5
160. Tena-Campos, M., Ramon, E., Borroto-Escuela, D. O., Fuxe, K., and Garriga, P. (2015). The zinc binding receptor GPR39 interacts with 5-HT1A and GalR1 to form dynamic heteroreceptor complexes with signaling diversity. Biochim. Biophys. Acta 1852, 2585–2592. doi: 10.1016/j.bbadis.2015. 09.003
161. Tena-Campos, M., Ramon, E., Lupala, C. S., Pérez, J. J., Koch, K. W., and Garriga, P. (2016). Zinc is involved in depression by modulating G protein-coupled receptor heterodimerization. Mol. Neurobiol. 53, 2003–2015. doi: 10.1007/s12035-015-9153-y
162. Trifilieff, P., Rives, M. L., Urizar, E., Piskorowski, R. A., Vishwasrao, H. D., Castrillon, J., et al. (2011). Detection of antigen interactions ex vivo, by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 51, 111–118. doi: 10.2144/000 113719
163. Van Craenenbroeck, K., Borroto-Escuela, D. O., Romero-Fernandez, W., Skieterska, K., Rondou, P., Lintermans, B., et al. (2011). Dopamine D4 receptor oligomerization–contribution to receptor biogenesis. FEBS J. 278, 1333–1344. doi: 10.1111/j.1742-4658.2011.08052.x
164. Veerakumar, A., Challis, C., Gupta, P., Da, J., Upadhyay, A., Beck, S. G., et al. (2014). Antidepressant-like effects of cortical deep brain stimulation coincide with pro-neuroplastic adaptations of serotonin systems. Biol. Psychiatry 76, 203–212. doi: 10.1016/j.biopsych.2013.12.009
165. Verma, V., Hasbi, A., O’Dowd, B. F., and George, S. R. (2010). Dopamine D1–D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: dual functional regulation by G protein-coupled receptor kinase 2. J. Biol. Chem. 285, 35092–35103. doi: 10.1074/jbc.M109.088625
166. Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., and Telang, F. (2011). Addiction: beyond dopamine reward circuitry. Proc. Natl. Acad. Sci. U S A 108, 15037–15042. doi: 10.1073/pnas.1010654108
167. Von Euler, G., and Fuxe, K. (1987). Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes. Acta Physiol. Scand. 131, 625–626. doi: 10.1111/j.1748-1716.1987.tb08285.x
168. Waldhoer, M., Fong, J., Jones, R. M., Lunzer, M. M., Sharma, S. K., Kostenis, E., et al. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U S A 102, 9050–9055. doi: 10.1073/pnas.0501112102
169. Wang, M., Pei, L., Fletcher, P. J., Kapur, S., Seeman, P., and Liu, F. (2010). Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. Mol. Brain 3:25. doi: 10.1186/1756-6606-3-25
170. Wieronska, J. M., Zorn, S. H., Doller, D., and Pilc, A. (2016). Metabotropic glutamate receptors as targets for new antipsychotic drugs: historical perspective and critical comparative assessment. Pharmacol. Ther. 157, 10–27. doi: 10.1016/j.pharmthera.2015.10.007
171. Winton-Brown, T. T., Fusar-Poli, P., Ungless, M. A., and Howes, O. D. (2014). Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 37, 85–94. doi: 10.1016/j.tins.2013.11.003
172. Wirz, S. A., Davis, C. N., Lu, X., Zal, T., and Bartfai, T. (2005). Homodimerization and internalization of galanin type 1 receptor in living CHO cells. Neuropeptides 39, 535–546. doi: 10.1016/j.npep.2005.09.001
173. 2Areceptors in cocaine-induced reward: a pharmacological and neurochemical analysis in rats. Psychopharmacology 232, 421–435. doi: 10.1007/s00213-014-3675-2
174. Wydra, K., Suder, A., Borroto-Escuela, D. O., Filip, M., and Fuxe, K. (2015b). On the role of A(2)A and D(2) receptors in control of cocaine and food-seeking behaviors in rats. Psychopharmacology (Berl) 232, 1767–1778. doi: 10.1007/s00213-014-3818-5
175. Young, L. J., and Wang, Z. (2004). The neurobiology of pair bonding. Nat. Neurosci. 7, 1048–1054. doi: 10.1038/nn1327
176. Zhang, H., Li, T., Li, S., and Liu, F. (2016). Cross-talk between α7 nAchR and NMDAR revealed by protein profiling. J. Proteomics 131, 113–121. doi: 10.1016/j.jprot.2015.10.018
177. Zoli, M., Agnati, L. F., Hedlund, P. B., Li, X. M., Ferré, S., and Fuxe, K. (1993). Receptor–receptor interactions as an integrative mechanism in nerve cells. Mol. Neurobiol. 7, 293–334. doi: 10.1007/BF02769180